China-based antibody drug developer Akeso Biopharma collected $150m in a series D round on Saturday co-led by pharmaceutical firm Sino Biopharmaceutical and private equity firm Loyal Valley Capital.
Conglomerate K. Wah Group also took part in the round, as did Shenzhen Capital Group, Lake Bleu Capital, China Reform Conson Soochow Overseas Fund I, OrbiMed Healthcare Fund Management and CCB Capital, the investment arm of financial services firm China Construction Bank.
The round additionally featured a range of undisclosed investors.
Founded in 2012, Akeso is developing treatments for a wide range of inflammatory, autoimmune and cardiovascular diseases, as well as cancer.
The series D capital has been allocated to the research and development of several drug candidates, collaboration agreements with external companies and recruitment.
Akeso previously attracted more than $14m in a series C round backed by Shenzhen Capital Group, Ally Bridge and TriWise Capital in October 2018, according to China Money Network.
Human resources firm Qianhai Xino contributed to a $45m a series B round led by GTJA Investment Group in 2017, investing alongside Shenzhen Capital Group, Qianhai Fund of Funds and TriWise Capital.
Qianhai Xino, Shenzhen Capital Group and CCB Principal Capital Management had already taken part in a $20m series A round in 2015.
